Terminal Sterilization Services Market (2025 - 2033)

Terminal Sterilization Services Market Summary

The global terminal sterilization services market size was estimated at USD 13.09 billion in 2024 and is projected to reach USD 25.54 billion by 2033, growing at a CAGR of 7.76% from 2025 to 2033. The increasing prevalence of healthcare-associated infections and the rising number of surgical procedures are the primary driving factors contributing to the industry growth.

The increasing prevalence of healthcare-associated infections (HAIs) is projected to contribute significantly to the growth of the terminal sterilization services industry. Hospitals & Clinics are under continuous pressure to improve sterilization standards to prevent infections caused by inadequately sterilized equipment. For instance, according to data released by the European Centre for Disease Prevention and Control, a European Union Agency, in May 2024, approximately 4.3 million hospitalized patients across the EU and European Economic Area (EEA) are affected by HAIs annually. These infections pose serious health risks and place a significant strain on healthcare systems.

This reflects a serious public health concern and highlights the financial and operational burden placed on hospitals and healthcare systems. As a result, healthcare providers and regulatory authorities are placing increased emphasis on terminal sterilization services processes to ensure product sterility and reduce infection risk.

Terminal sterilization, performed after packaging, ensures microbial inactivation, making it an essential step in infection prevention protocols. This escalating demand for effective infection controls due to growing healthcare-associated infections is anticipated to propel the market for terminal sterilization services significantly.

Another major factor driving the industry growth is the growing surgical procedures in hospitals. For instance, according to a Eurostat report, the two most common surgical operations and procedures performed in EU hospitals are cataract surgery and caesarean sections.

Surgical Operations and Procedures Performed in Hospitals & Clinic - Top 10 Procedures, Group 1, 2022

Source: Eurostat

Surgical Operations and Procedures Performed in Hospitals & Clinic - Top 10 Procedures, Group 2, 2022

Source: Eurostat

Stringent regulatory oversight from global health authorities is pivotal in accelerating the growth of the terminal sterilization services industry. Agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO) have all emphasized the importance of validated Sterility Assurance Levels (SAL) for medical devices, surgical instruments, and sterile pharmaceutical products before market approval.

The FDA and EMA strongly advocate using terminal sterilization services, wherever feasible, as the preferred method of achieving sterility. The WHO's Good Manufacturing Practices (GMP) for sterile pharmaceutical products similarly recommend:

"Whenever possible, products intended to be sterile should be terminally sterilized by heat in their final container."

This preference is further highlighted in the European Pharmacopoeia, which states:

"Wherever possible, a process in which the product is sterilized in its final container (terminal sterilization services) is chosen."

In addition, the FDA's updated guidance published in January 2024 highlights a noticeable increase in 510(k) submissions involving non-traditional sterilization methods, underscoring growing innovation and complexity in the field. However, the guidance also draws clear boundaries by excluding:

• Sterilizers that are themselves medical devices

• Processes relying on microbial exclusion

• Devices containing materials of animal origin

• Liquid chemical sterilization processes

• Reprocessing methods for single-use devices

• Sterile reprocessing procedures at healthcare facilities

The FDA's 2024 guidance specifies that 510(k) submissions using established sterilization methods must include a process description, specifications, 510(k) clearance status, and sterilization validation summary. While validation data is not required, the submission must confirm an SAL of 10⁻⁶ for sterile-labeled devices, unless intended only for intact skin contact. This reinforces the FDA's focus on industrial terminal sterilization services processes based on microbial inactivation, especially for devices labeled as sterile.

Further strengthening the demand for terminal sterilization services, Health Canada's guidance document published in November 2024 defines terminal sterilization services as the application of a lethal sterilizing agent to a finished product sealed in its final container, aiming to achieve a Sterility Assurance Level (SAL) of 10⁻⁶ or better. The document emphasizes that terminal sterilization services are the preferred method for producing sterile products, as they offer more sterility assurance than in-process sterilization.

Major Brands Operating in the Market

Source: Company Websites

Key Opinion Leaders Responses

Source: Company Websites

Market Concentration & Characteristics

The global terminal sterilization services industry demonstrates a high degree of innovation, driven by growing regulatory requirements, the demand for safer and more eco-friendly methods, and advances in healthcare technology. For instance, in May 2025, MATACHANA announced the launch of its NEW S1000 Steam Sterilizer, featuring improved energy efficiency, faster cycle times, and advanced automation. This exemplifies the industry’s move toward smarter and more sustainable sterilization solutions.

Regulations play a critical role by setting safety, efficacy, and environmental standards that manufacturers must meet. Stringent regulatory requirements drive innovation and the adoption of advanced sterilization technologies, ensuring patient safety while encouraging the development of more efficient and sustainable sterilization methods. For instance, in January 2024, the FDA approved vaporized hydrogen peroxide (VHP), a low-temperature sterilization technique, for medical device sterilization. This authorization facilitated broader adoption of VHP within the medical device industry. Such regulatory approvals are expected to accelerate the use of VHP, opening new opportunities for market growth and technological advancement in the coming years.

M&A activity has become pronounced as companies seek to expand services and geographic reach and adopt advanced technologies like electron beam and vaporized hydrogen peroxide sterilization. These acquisitions help firms improve efficiency, diversify portfolios, and meet growing healthcare demands. For example, in August 2023, Orrick represented Ionisos in the acquisition through a carve-out of an E-beam sterilization and crosslinking facility from Studer Cables AG in Däniken, Switzerland.

Product substitutes include alternative methods such as aseptic processing, which is commonly used in pharmaceutical manufacturing to maintain sterility without applying terminal processes. High-level disinfection (HLD) is a substitute for semi-critical medical devices where complete sterility is not required. Sterile filtration (membrane filtration) is also another product substitute that helps remove microorganisms from liquids or gases before packaging.

The market for terminal sterilization services is moderately to highly concentrated, dominated by key players such as ASP (Fortive), STERIS, Getinge, and Sterigenics U.S., LLC - A Sotera Health company, among others, who leverage extensive service networks and regulatory expertise. High entry barriers like strict regulations and costly infrastructure limit new competition, though regional and specialized providers add diversity, especially in emerging markets. For instance, in June 2025, Solventum launched the Attest Super Rapid Vaporized Hydrogen Peroxide (VH₂O₂) Clear Challenge Pack, a single-use test combining FDA-cleared biological and chemical indicators in a transparent pack, reflecting continued innovation in the sterilization space.

Product Insights

Based on product, the equipment segment held the largest revenue share of 41.81% in 2024. This segment includes steam autoclaves, ethylene oxide sterilizers, and hydrogen peroxide (H₂O₂) sterilizers, including plasma-based systems, which serve as the technological foundation of terminal sterilization services in healthcare, pharmaceutical, and medical device industries. These sterilization systems are essential for ensuring the sterility of medical instruments, drugs, and packaged devices, with each type designed to accommodate specific material sensitivities, sterility assurance requirements, and operational demands.

Modern terminal sterilization service equipment is evolving rapidly to meet the demands of efficiency, safety, and regulatory compliance. Key advancements include digital monitoring, shorter sterilization cycles, and automated validation systems, all of which significantly improve workflow, reduce human error, and ensure consistent sterilization performance. For instance, in June 2024, Getinge introduced the Poladus 150, its latest low-temperature sterilizer, to address the increasing need for safe and effective reprocessing of heat-sensitive surgical instruments. Utilizing vaporized hydrogen peroxide (VH₂O₂) and operating at a controlled temperature of up to 55°C, the Poladus 150 is engineered to sterilize non-lumen, flexible lumen, and rigid lumen instruments, making it highly suitable for the complex requirements of endoscopic and robotic surgeries.

The consumables segment is expected to witness a CAGR of 7.84% during the forecast period, driven by the rising demand for rapid sterilization verification, increased surgical procedures, and stricter infection control regulations. For instance, in August 2025, Advanced Sterilization Products (ASP) introduced the BIOTRACE Instant Read Steam Biological Indicator System, which reportedly delivers results in just seven seconds. This innovation significantly enhances workflow efficiency by eliminating delays, supporting continuous operation, and ensuring speed, accuracy, and confidence in every sterilization cycle. Growing investments in terminal sterilization services and the shift toward automation in central sterile services departments (CSSDs) further support the strong demand for high-performance consumables.

Method Insights

In terms of method, the low temperature sterilization segment accounted for the largest share in 2024. The low temperature method has gained prominence in the terminal sterilization services industry due to its effectiveness in sterilizing heat- and moisture-sensitive medical devices. Using chemical agents, such as ethylene oxide (EtO), hydrogen peroxide gas plasma, ozone, and vaporized peracetic acid, the method ensures sterility without damaging delicate instruments. It is increasingly preferred for sterilizing minimally invasive surgical tools, flexible endoscopes, and implantable devices. Market growth is driven by the rise in reusable medical equipment, the expansion of outpatient surgical centers, and advancements that reduce cycle times and enhance sterilization efficiency.

For instance, in January 2024, the U.S. FDA officially recognized Vaporized Hydrogen Peroxide (VHP) as an established sterilization method for medical devices, boosting its credibility and adoption. VHP is highly effective against resistant pathogens like C. difficile and MRSA and can penetrate small lumens and cavities, making it ideal for sterilizing complex instruments. With growing concerns over hospital-acquired infections, healthcare facilities increasingly turn to VHP sterilizers to ensure adequate disinfection of critical devices such as endoscopes and surgical tools.

“The FDA’s commitment is to protect public health, a critical mission in today’s complex medical device ecosystem,” said Suzanne Schwartz, M.D., M.B.A., director of the Office of Strategic Partnerships and Technology Innovation in the FDA’s Center for Devices and Radiological Health. “Vaporized hydrogen peroxide’s addition as an established sterilization method helps us build a more resilient supply chain for sterilized devices that can help prevent medical device shortages. As innovations in sterilization advance, the FDA will continue to seek additional modalities that deliver safe and effective sterilization methods that best protect public health.”

The high temperature (steam sterilization) segment is expected to witness healthy growth over the forecast period. High temperature sterilization, primarily through steam sterilization (autoclaving), remains among the most established and widely used methods in the industry. Operating at 121°C to 134°C eliminates a broad range of microorganisms, including spores, making it ideal for heat- and moisture-resistant devices, including surgical tools, stainless steel instruments, and reusable glassware. Known for its cost-effectiveness, reliability, and environmental safety, it is prevalent in hospitals, surgical centers, and labs. Despite the rise of low-temperature methods for sensitive devices, high-temperature sterilization continues to dominate due to its simplicity, short cycle times, and proven efficacy.

The increasing number of surgical procedures is a major driver of this segment. As the volume of surgical procedures rises, there is a heightened need for effective sterilization methods to ensure patient safety and prevent healthcare-associated infections. In addition, the rising global focus on infection control, particularly in the wake of hospital-acquired infections, has increased the demand for effective and validated sterilization systems.

End-use Insights

On the basis of end use, the hospitals & clinic segment captured the largest revenue share in 2024. Hospitals & clinic drive demand for terminal sterilization services as they ensure the highest level of device sterilization, which is critical for patient safety by eliminating all microorganisms and reducing healthcare-associated infections. With rising surgeries, stricter regulations, and increased infection awareness, hospitals prioritize terminal sterilization services to meet standards, improve outcomes, and comply with laws, avoiding costly recalls and reputational damage. For instance, in August 2025, the International Trade Administration highlighted Brazil as the most significant healthcare market in Latin America, spending 9.7% of its GDP (US$135 billion) on healthcare, with 7,309 hospitals (63% private), over 500,000 beds, nearly 576,000 physicians, and a public system (SUS) serving 72% of the population.

The ambulatory surgery centers segment is anticipated to experience the fastest growth over the forecast period, driven by increasing preference for outpatient procedures and expansion of ambulatory surgery center facilities, among others. For instance, according to UPMC HealthBeat, an integrated health care system based in Pittsburgh, reports that many procedures and surgeries are now routinely performed on an outpatient basis. Common outpatient procedures and types of outpatient surgeries include:

• Cataract surgery: Removing the cloudy natural lens of the eye and replacing it with an artificial lens.

• Ear, nose, and throat (ENT) surgeries: Such as tonsil and adenoid removal.

• Cosmetic surgeries: Including breast reconstruction and skin grafts.

• Urologic procedures: Such as vasectomy.

• Orthopedic procedures: Including knee and hip replacements, as well as surgeries on toes, feet, ankles, and legs.

• Gallbladder removal.

• Skin procedures: Such as mole removal and other skin repairs.

• Lumpectomy: Removal of a cancerous tumor in the breast.

• Colonoscopy and endoscopy.

• Hand, wrist, elbow, and ankle surgeries: Including procedures for arthritis.

• Tendon and muscle repairs: Such as rotator cuff surgery.

• Gynecological procedures: Including dilation and curettage (D&C) and tubal ligation.

• Hemodialysis: For patients with kidney disease.

• Hernia repairs.

• Hemorrhoid procedures.

• Kidney stone treatment

Regional Insights

North America terminal sterilization services market accounted for the largest revenue share of 34.60% in 2024, driven by the increasing demand for infection control and patient safety in healthcare settings. The region is witnessing significant growth, primarily fueled by the rising incidence of healthcare-associated infections (HAIs), increasing surgical procedure volumes, and the growing need for effective infection control across hospitals and medical facilities. Stricter regulatory standards set by agencies like the FDA and CDC have amplified the demand for validated sterilization services, especially in the pharmaceutical and medical device industries. In addition, the rise in chronic diseases, an aging population requiring more invasive treatments, and the expansion of the biologics and personalized medicine sectors have further fueled the need for terminal sterilization services. Outsourcing trends among pharma and MedTech companies and advancements in sterilization technologies, such as low-temperature hydrogen peroxide and irradiation methods, support market expansion by offering safer, faster, and environmentally friendly alternatives to traditional methods like ethylene oxide.

U.S. Terminal Sterilization Services Market Trends

The terminal sterilization services industry in the U.S. contributed the largest share of 88.89% (in North America) in 2024. The U.S. market is primarily driven by the growing demand for infection control and the increasing volume of surgical procedures and hospital admissions. According to a report by the CDC in November 2023, approximately one in 31 hospital patients and one in 43 nursing home residents in the U.S. acquire at least one healthcare-associated infection each day. This highlights the need to strengthen infection prevention measures across all healthcare settings. Despite notable progress in recent years, further improvements are essential to enhance patient safety and reduce the burden of HAIs throughout the U.S. healthcare system. With the rising burden of chronic conditions such as diabetes, cardiovascular diseases, and cancer, the need for surgeries and sterile surgical instruments has grown significantly. Furthermore, the continued use of implantable and disposable medical devices, including catheters, pacemakers, and orthopedic implants, has intensified the reliance on terminal sterilization services to ensure patient safety. The ongoing emphasis on hospital-acquired infection reduction, especially post-COVID-19, has also compelled healthcare facilities to strengthen sterilization protocols.

Europe Terminal Sterilization Services Market Trends

The European terminal sterilization services industry is spurred by growing focus on infection control, rising surgical volumes, and strict enforcement of sterilization standards. It is largely fueled by an aging population and increased chronic diseases. The EU’s Medical Device Regulation (MDR) has heightened emphasis on product safety, pushing adoption of validated sterilization processes. Growth is also supported by increased use of single-use devices and expansion in the pharmaceutical and biotech sectors. Awareness of healthcare-associated infections and government efforts to improve hygiene further boost demand for advanced sterilization solutions. For instance, in October 2024, the Medical Device Coordination Group clarified that ethylene oxide (EtO) used for sterilizing medical devices is regulated under MDR/IVDR, not the Biocidal Products Regulation, exempting it from specific biocide rules.

The terminal sterilization services industry in the UK is expected to grow consistently, primarily augmented by stringent healthcare regulations and an increasing emphasis on infection prevention and patient safety. The country's aging population plays a significant role in this growth trajectory. According to the Centre for Ageing Better, around 11 million people in England were aged over 65 as of 2023, with projections indicating a 10% rise in the next five years and a 32% increase by 2043. Older adults are more susceptible to chronic diseases, often requiring hospitalization for surgeries and other medical procedures. This demographic trend is anticipated to raise the demand for sterile medical equipment, thereby boosting the adoption of terminal sterilization services across healthcare facilities.

In addition, the high incidence of healthcare-associated infections (HAIs) is a pressing concern driving market expansion. For instance, in March 2025, the UK Health Security Agency report for 2023 noted that approximately 7.6% of hospitalized patients were affected by healthcare-associated infections (HAIs). This alarming rate has intensified the focus on infection control, prompting hospitals and clinics to strengthen sterilization protocols. Terminal sterilization plays a crucial role in ensuring medical devices, surgical tools, and pharmaceuticals meet sterility standards, making it essential to healthcare operations. With growing awareness of HAIs and increasing regulatory scrutiny, demand for terminal sterilization services is expected to rise significantly across the UK healthcare sector.

Asia Pacific Terminal Sterilization Services Market Trends

The Asia-Pacific terminal sterilization services industry is growing rapidly, driven by healthcare modernization and increased surgical volumes in countries such as China, India, Japan, and Australia. Ethylene oxide remains the dominant sterilization method, while radiation and low-temperature techniques gain popularity for heat-sensitive products. Outsourced sterilization services are favored by device manufacturers, pharma companies, and hospitals for efficiency and compliance. Market leaders are expanding into new regions, tailoring solutions to local needs. Rising healthcare-associated infections, aging populations, and chronic diseases further drive demand for professional sterilization across the region.

The terminal sterilization services industry in China is experiencing rapid growth driven by healthcare expansion, regulatory modernization, and rising industrial demand. The development of hospital infrastructure, especially in Tier II and III cities, has increased the need for validated sterilization to support higher surgical volumes and infection control. In contrast, government emphasis on infection prevention has accelerated the adoption of advanced technologies in public and private hospitals. For instance, in January 2024, the NIH published a report noting that MRSA detection rates in Macau rose from 30.1% in 2017 to 45.7% in 2022, highlighting the urgent need for stringent sterilization. In addition, the shift toward contract sterilization services is gaining momentum among small and mid-sized manufacturers aiming to reduce operational burdens and ensure regulatory compliance. The government’s promotion of green sterilization practices, including limiting ethylene oxide emissions and encouraging energy-efficient equipment, further supports the rapid modernization and expansion of China in the global landscape.

Latin America Terminal Sterilization Services Market Trends

The Latin America terminal sterilization services industry is growing rapidly, underscored by rising healthcare demand, stricter regulations, and technological advancements. A key growth factor is the increasing rate of hospital-acquired infections, pushing healthcare facilities to adopt more stringent sterilization practices to enhance patient safety. While urban hospitals in Latin America have improved sterile processing standards, significant disparities persist in rural and regional areas. An expert panel of SPD professionals from five Latin American countries convened in São Paulo, supported by 3M Health Care, to review best practices, share challenges, and develop guidance for improving SPD performance across the region.

Middle East and Africa Terminal Sterilization Services Market Trends

The Middle East and Africa (MEA) terminal sterilization services industry is growing, furthered by rising surgical volumes, increased focus on infection prevention, and higher healthcare-associated infections (HAIs) rates. Demand is strong across hospitals, outpatient centres, and medical manufacturing sites, with notable low-temperature and radiation sterilization equipment growth. Hospitals & clinic and manufacturers increasingly outsource sterilization services to ensure regulatory compliance and efficiency. The pharmaceutical and biopharmaceutical sectors, especially sterile drug and vaccine producers are significant growth drivers. Within the broader infection control market, services are expanding faster than consumables and equipment, reflecting a stronger emphasis on hygiene protocols across the MEA region. For instance, in January 2025, De Lama presented the latest sterilization, washing, and decontamination equipment innovations at the DUPHAT Pharma exhibition in Dubai. Highlights included advanced solutions designed to meet the stringent requirements of the new Annex 1 guidelines and the HyPerPure Hydrogen Peroxide sterilizer, recognized as the most efficient and environmentally friendly sterilizer currently available on the market.

Key Terminal Sterilization Services Company Insights

The industry is moderately fragmented, featuring major global players and local competitors. As companies intensify their efforts to capture market share, competition is expected to become increasingly fierce. Many participants are pursuing strategic initiatives such as product launches, mergers and acquisitions, and geographic expansion to strengthen their competitive position. With these diverse strategies in play, the terminal sterilization services industry will experience significant growth during the forecast period.

Recent Developments

• In June 2025, Solventum announced the launch of its Attest Super Rapid Vaporized Hydrogen Peroxide (VH2O2) Clear Challenge Pack. This ready-to-use test combines two FDA-cleared indicators- a biological indicator (BI) that confirms microbial neutralization and a chemical indicator (CI) that verifies proper sterilizer performance- into a single-use pack featuring a transparent container.

• In May 2025, Sterigenics, a Sotera Health company and one of the leading global providers of outsourcing terminal sterilization services, announced the expansion of its Haw River, North Carolina campus to include a new X-Ray facility situated next to its existing gamma facility. The new facility is scheduled to open in late 2025.

• In April 2025, DE LAMA S.P.A. announced that it was awarded as the Top Sterilization Company in Europe for 2025 by the authoritative PharmaTech Outlook magazine. One of the company's major innovations is HyPerPure, a sterilization technology that addresses the limitations of traditional methods. For instance, when a pharmaceutical client required sterilization of a heat-sensitive syringe containing blood derivatives, conventional techniques proved inadequate. HyPerPure reportedly provided reliable sterilization for temperature-sensitive products, reduced energy consumption by 70% compared to saturated steam sterilization, and eliminated water waste, thereby significantly decreasing environmental impact and operating costs.

• In March 2025, the CASP announced that it successfully obtained the da Vinci test report for its Hydrogen Peroxide Low Temperature Plasma Sterilizers.

• In November 2024, ASP was recognized with four esteemed 2024 Medical Device Network Excellence Awards. These awards in the categories of Innovation, Product Launch, Safety, and Environmental reflect the company's dedication to advancing sterilization technology, enhancing healthcare safety, and promoting sustainability.

• In August 2024, ASP in collaboration with PENTAX Medical, a division of HOYA Group, announced the FDA clearance of the new ULTRA GI Cycle for its flagship product, the STERRAD 100NX Sterilizer with ALLClear Technology. The ULTRA GI Cycle is specifically and uniquely designed to reprocess duodenoscopes using hydrogen peroxide gas plasma sterilization.

• In May 2024, MATACHANA obtained MDR certification for its extensive range of steam and low-temperature sterilizers.

• In March 2024, Prince Sterilization Services, LLC enhanced its contract sterilization offerings by adding in-house low-temperature hydrogen peroxide terminal sterilization services capabilities for medical devices.

• In February 2024, NovaSterilis received a USD 1.75 million SBIR (Small Business Innovation Research) Phase II grant from the NIAID (National Institute of Allergy and Infectious Diseases). This funding advances the development of NovaSterilis’ scCO2-based terminal sterilization services platform for the pharmaceutical and biotechnology sectors.

Terminal Sterilization Services Market